Connecting new science, research and healthcare needs: is the contract between society and pharmaceutical industry up for renewal?

Science is changing! New ways of collaborating in scientific research are revolutionising results and outcomes. New findings are leading to a reclassification of diseases which is consequently changing the way patients are treated and healthcare is delivered.

However, are healthcare systems flexible and versatile enough to adapt to new scientific findings? Is society ready for a new science paradigm? Is the contract between society and pharmaceutical industry up for renewal?

This session will seek stakeholders’ views on:

- how to translate research and science into concrete benefits for patients
- how the industry and society can develop common agendas towards a new model that links knowledge to adequate patient access
- how will pressured healthcare systems respond to new evidence and treatments

Speakers

C Longson, Director, Centre for Health Technology Evaluation, NICE, UK
M Goldman, Executive Director, Innovative Medicines Initiative
S Marschang, Policy Coordinator for Health Systems, European Public Health Alliance
J Attridge, Research Fellow, Imperial College, UK
P Andersen, Senior Vice President, Global Public Affairs and Corporate Patents and Trademarks, H Lundbeck A/S, Denmark

Moderated by T Jones, Director, Allergan INC